ClinicalTrials.gg
TerminatedNCT05810961Updated Nov 22, 2024

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

A Phase 2 interventional study of efgartigimod IV and placebo in Membranous Nephropathy, sponsored by argenx. Terminated at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Enrollment
46th of 50
8 · median 77
Started
2023
with 7 others
Phase 2
11 of 60
6 open now
Registered
31st of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 46th largest by enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2023, is one of 11 in phase 2, and was the 31st registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).

Read the detailed description

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).The study comprises a maximum 4-week screening period, a 24-week treatment period, and an 8-week follow-up period

03

Conditions studied

  • Membranous Nephropathy

Keywords

  • kidney disease
  • Glomerulonephritis membranous
  • Urologic disease
  • glomerulonephritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years when signing the form (ICF)
  • Capable of providing signed informed consent and complying with protocol requirements
  • Diagnosis of idiopathic (primary) MN confirmed by renal within 24 months before randomization. A renal biopsy may be taken at any time during the screening period to confirm the diagnosis of MN for participant eligibility, if the most recent biopsy was performed greater than 24 months before randomization
  • Receiving stable dose at maximum tolerated or allowed dose of ACEi and/or ARB for at least 12 weeks before randomization
  • Agree to use consistent with local regulations. Full inclusion criteria can be found in the protocol

Exclusion criteria

Exclusion Criteria:

  • Active or chronic infection requiring treatment
  • Diagnostic renal showing evidence of crescent formation in glomeruli, suggestive of an alternative or additional diagnosis to pMN; evidence on renal biopsy of >50% interstitial fibrosis/tubular atrophy in the cortical area
  • History of unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before randomization.
  • Any evidence of diabetic glomerulopathy on renal biopsy that is:

Greater than Class I diabetic glomerulopathy, or Class I diabetic glomerulopathy with a history of poor diabetic control (eg, ≥9.0%) since time of biopsy

  • Currently on renal dialysis or expected to require dialysis during study period
  • Previous kidney transplantation or planned transplantation during study period
  • Any other known disease that, requires systemic treatments, or in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of pMN or put the participant at undue risk
  • Clinical evidence of other significant or uncontrolled serious diseases (ie, cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological), have had a recent major surgery, or have any other condition, that in the opinion of the investigator, could confound the results of the study or put the participant at undue risk
  • Use of complementary therapies, including Traditional Chinese Medicine, herbs, or procedures (eg, acupuncture) within 4 weeks before randomization that can potentially interfere with the efficacy and safety of participants as assessed by the investigator
  • Received live/ within 28 days before randomization. The receipt of any inactivated, subunit, polysaccharide, or conjugate vaccine at any time before screenings is not considered exclusionary. It is recommended that participants are up to date with vaccination before the first dose of IMP
  • Previously participated in a clinical study with efgartigimod
  • SARS-CoV-2 positive test at screening. The test is required regardless of whether the participant has been vaccinated
  • Known or to efgartigimod, or any of the IMP
  • In the opinion of the investigator, current or history of (ie, within 12 months of randomization) alcohol, drug, or medication abuse
  • Pregnant or lactating females and those who intend to become pregnant during study participation
  • Any conditions or circumstances that in the opinion of the investigator may make the participant unsuitable for the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    efgartigimod IV

    patients receiving infusions of efgartigimod

    Biological: efgartigimod IV

  • Experimental
    placebo

    patients receiving infusions of placebo

    Other: placebo

Interventions

  • Biologicalefgartigimod IV

    infusion of efgartigimod

  • Otherplacebo

    infusion of placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline to week 24 in urine protein creatinine ratio (UPCR) in anti- PLA2R antibody (Ab) seropositive population

    Time frame: up to 24 weeks

Secondary outcomes

  1. Change from baseline to week 24 in urine protein creatinine ratio (UPCR) in overall population

    Time frame: up to 24 weeks

  2. Proportion of participants achieving complete remission (CR), defined as proteinuria ≤0.3g/24-hour and serum albumin ≥3.5g/dL, at week 24 in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 24 weeks

  3. Time to complete remission (CR) in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 32 weeks

  4. Proportion of participants achieving partial remission (PR), defined as ≥50% reduction in proteinuria from baseline AND final proteinuria between 0.3 to 3.5g/24-hour, at week 24 in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 24 weeks

  5. Time to partial remission (PR) in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 32 weeks

  6. Change from baseline to week 24 in anti-PLA2R Ab in anti-PLA2R Ab seropositive population

    Time frame: up to 24 weeks

  7. Change from baseline to week 24 in serum albumin in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 24 weeks

  8. Change from baseline to week 24 in estimated glomerular filtration rate (eGFR) in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 24 weeks

  9. Treatment failure rate during treatment period in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 32 weeks

  10. Incidence of relapse, defined as the development of nephrotic range proteinuria following CR or PR, ie, >3.5g/24-hour throughout the study in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 32 weeks

  11. Efgartigimod serum concentration-time profile in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 32 weeks

  12. changes from baseline in levels of total IgG

    Time frame: up to 32 weeks

  13. Incidence of antidrug antibodies (ADA) against efgartigimod in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 32 weeks

  14. Change from baseline in EQ5D-5L score in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 24 weeks

  15. Change from baseline in PROMIS Short form v1.0 Fatigue-4a questionnaire in overall population and anti-PLA2R Ab seropositive population

    Time frame: up to 24 weeks

07

Study locations

31 sites
  • Peking University People's Hospital
    Beijing, China
  • Hunan Provincial People's Hospital
    Changsha, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Fujian Medical University Union Hospital
    Fujian, China
  • Fuyang People's Hospital
    Fuyang, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guanzhou, China
  • The First Affiliated Hospital, Zhejiang University
    Hanzhou, China
  • The Second Hospital of Anhui Medical University
    Hefei, China
  • The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University
    Huai'an, 223300, China
  • Shandong Provincial Hospital Affiliated to Shandong First Medical University
    Jinan, China
  • Liu Zhou Works Hospital
    Liuzhou, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
  • Jiangsu Province Hospital
    Nanjing, China
  • Zhongda Hospital Southeast University
    Nanjing, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, China
  • Pingxiang People's Hospital
    Pingxiang, 337055, China
  • Huashan Hospital Fudan University
    Shanghai, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, China
  • ShengJing Hospital of China Medical University
    Shenyang, China
  • Shenzhen People's Hospital
    Shenzhen, China
  • The First Hospital of Hebei Medical University
    Shijia Zhuang, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, China
  • Renmin Hospital of Wuhan University
    Wuhan, China
  • Wuxi People's Hospital
    Wuxi, China
  • Shaanxi Provincial Hospital of Chinese Medicine
    Xi'an, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
  • Xiamen Fifth Hospital
    Xiamen, China
  • Henan Provincial People's Hospital
    Zhengzhou, China
  • Zhuhai People's Hospital
    Zhuhai, 519099, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Aug 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 13, 2023
StartActual
Feb 20, 2023
Primary completionActual
Aug 5, 2024
CompletionActual
Aug 5, 2024
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05810961
Lead sponsor
argenx
Collaborators
Zai Lab Pty. Ltd.
Responsible party
Sponsor
First posted
Apr 13, 2023
Start date
Feb 20, 2023
Primary completion
Aug 5, 2024
Completion
Aug 5, 2024
Last update
Nov 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion